Safety Pharmacology

Safety Pharmacology is an essential element of most small-molecule development programs and accompanies the general toxicology for IND filings. At Frontage, we provide an incorporated approach to GLP regulatory safety pharmacology and early non-GLP discovery pharmacology testing performed according to ICH S7A and S7B compliance from research and development to IND submission. Regardless of the approach, the molecule, or the therapeutic indication, Frontage can support your Safety Pharmacology services needs.

We offer a core battery of studies for in vitro & in vivo cardiovascular (CV) testing as well as neuroscience (CNS) and respiratory assessments for your non-clinical programs.

CNS Safety Assessments

At Frontage we conduct CNS safety assessment either as stand-alone or as an embedded endpoint in the general toxicology study.

In-Vivo CNS (Irwin, Functional Observational Battery)

Locomotor activity
Behavior
Coordination
Sensory Motor reflex
Body temperature

Cardiovascular Safety Assessments

At Frontage, we offer both in vitro and in vivo cardiovascular safety assessment services.

In-Vitro CV

Standard hERG Ion Channel Study
CiPA-Compliant Version of the Study
Additional Ion channel Evaluations Cav1.2 and Nav1.5 also Available

In-Vivo CV

Assay Consists of Evaluation of Cardiovascular Effects via Implanted Telemetry
- Blood Pressure
Systolic, Diastolic, Mean Arterial Blood Pressure
- Heart Rate
- Qualitative Assessment of Electrocardiographic Data by DVM,
  DACVIM veterinaria
- Quantitative Assessment of electrocardiogram
PR Interval, QRS Duration, QT Interval, and Corrected QT
- (QTcV) Interval
- Internal Temperature